A commercial concomitant medication used as part of a clincal study was classified as investigational by health authority and will be over labelled as IMP. Commercial product was procured in US and labeled as per regional label regulations for US export to North American region. Requesting guidance on if a package insert is required to accompany conmeds for clinical site if product is classified as IMP?